Morgan Stanley Maintains Equal-Weight on Foghorn Therapeutics, Raises Price Target to $9
Benzinga Newsdesk 2 years ago
NewsPrice TargetAnalyst Ratings
Morgan Stanley analyst Vikram Purohit maintains Foghorn Therapeutics (NASDAQ:FHTX) with a Equal-Weight and raises the price target from $6 to $9.
Morgan Stanley analyst Vikram Purohit maintains Foghorn Therapeutics (NASDAQ:FHTX) with a Equal-Weight and raises the price target from $6 to $9.